Insights
Long-form editorial on peptide science — what's changing in the literature, in the MHRA, and in the compounds researchers actually work with.
Topical GHK-Cu at 0.05–0.2% has the strongest human cosmetic data; injectable protocols come from rodent wound-healing studies. Here's how UK researchers separate the two.
Read the piece →Eli Lilly's Phase 2 obesity trial for retatrutide reported up to 24.2% mean weight reduction at 48 weeks. Here's the data in context.
Read the piece →The Ipamorelin + CJC-1295 (no-DAC) pairing is designed to mimic physiological GH pulses. Here's how UK researchers structure the protocol and why timing matters.
Read the piece →Semaglutide, tirzepatide and liraglutide hold UK marketing authorisations. Retatrutide, BPC-157, TB-500, GHK-Cu and most research peptides do not. Here's the current map.
Read the piece →Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.
